Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ibnsina PharmaCAI:ISPH +0.15%82 Return-on-Tangible-Asset is 2.59% as of Jun. 2026, which is 14% below its 10-year median of 3.02. GuruFocus rates CAI:ISPH with a GF Score™ of 82/100 and a GF Value™ of E£11.59 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 120 Medical Distribution companies, Ibnsina Pharma ranks better than 56.67% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Ibnsina Pharma's annualizedNet Income for the quarter that ended in Jun. 2026 was E£1,021 Mil. Ibnsina Pharma's average total tangible assets for the quarter that ended in Jun. 2026 was E£39,445 Mil. Therefore, Ibnsina Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 2.59%.
The historical rank and industry rank for Ibnsina Pharma's Return-on-Tangible-Asset or its related term are showing as below:
CAI:ISPH'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.37 Med: 3.02 Max: 4.53
Current: 2.93
During the past 10 years, Ibnsina Pharma's highest Return-on-Tangible-Asset was 4.53%. The lowest was 1.37%. And the median was 3.02%.
CAI:ISPH's Return-on-Tangible-Asset is ranked better than 56.67% of 120
companies
in the Medical Distribution industry
Industry Median: 2.485
vs CAI:ISPH: 2.93
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Ibnsina Pharma Return-on-Tangible-Asset Related Terms
Ibnsina Pharma Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Ibnsina Pharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI:ISPH vs MCK, COR, CAH: Return-on-Tangible-Asset Comparison
For the Medical Distribution subindustry, Ibnsina Pharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ibnsina Pharma Return-on-Tangible-Asset vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ibnsina Pharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Ibnsina Pharma's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 2.59% mean?
Ibnsina Pharma (CAI:ISPH) has a Return-on-Tangible-Asset of 2.59% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Ibnsina Pharma and its competitors. This is 14% below median its historical median of 3.02. Over the past decade, Ibnsina Pharma's Return-on-Tangible-Asset has ranged from 1.37 to 4.53. According to the industry distribution chart, Ibnsina Pharma ranks #52 out of 120 companies in the Medical Distribution industry, placing it in the top 43.3%.
Is Ibnsina Pharma's Return-on-Tangible-Asset too high?
Ibnsina Pharma's current Return-on-Tangible-Asset of 2.59% is 14% below median its 10-year median of 3.02. Over the past 10 years, this metric has ranged from a low of 1.37 to a high of 4.53. The Medical Distribution industry median Return-on-Tangible-Asset is 2.49. Ibnsina Pharma's value of 2.59% is 4.2% above this industry median. Based on the distribution chart, Ibnsina Pharma ranks #52 out of 120 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Ibnsina Pharma has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's Return-on-Tangible-Asset compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ibnsina Pharma ranks #52 out of 120 companies for Return-on-Tangible-Asset. This puts Ibnsina Pharma in the upper half of its industry. The industry median Return-on-Tangible-Asset is 2.49. Ibnsina Pharma's value of 2.59% is 4.2% above this benchmark. Historically, Ibnsina Pharma's own Return-on-Tangible-Asset has ranged from 1.37 to 4.53 over the past decade. While the company's 10-year median is 3.02 vs. the industry median of 2.49, Ibnsina Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Distribution company?
The median Return-on-Tangible-Asset among Medical Distribution companies is 2.49, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ibnsina Pharma's current Return-on-Tangible-Asset of 2.59% is 4.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Ibnsina Pharma and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Asset is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ibnsina Pharma's current Return-on-Tangible-Asset is 2.59%, which is 14% below median its own 10-year median of 3.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Modestly Overvalued. The stock's GF Value™ is E£11.59, compared to a current price of E£13.02 — trading 12.3% above its estimated fair value. The current Return-on-Tangible-Asset is 2.59%, which is 14% below median its 10-year median of 3.02 and 4.2% above the Medical Distribution industry median of 2.49. Ibnsina Pharma's overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current Return-on-Tangible-Asset is 2.59% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?
Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued.
The current stock price of E£13.02 is trading 12.3% above its estimated GF Value™ of E£11.59.
GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.
Key valuation signals for CAI:ISPH:
Return-on-Tangible-Asset: 2.59% (14% below median its 10-year median of 3.02)
GF Value™: E£11.59 vs. price of E£13.02 (12.3% above fair value)
Industry Position: 4.2% above the Medical Distribution median (#52 of 120)
No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
82GF Score
Get the complete analysis for CAI:ISPH
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:ISPH has been successfully added to your 
